Mr. Eisenschmid, I'm coming back to you.
Your organization has said that one model has really been discussed for Canada, and only one model, rather than considering multiple ones. Certainly at the committee all that we've heard has been largely to do with Pharmacare 2020. I haven't heard much expansion beyond that at this committee.
I'm hoping that today you could perhaps mention some other models that might be worth considering as well.